Published online 22 April 2002. doi:10.1083/jcb.200109100
© The Rockefeller University Press,
0021-9525/2002/4/493 $5.00
The Journal of Cell Biology, Volume 157, Number 3, April 29, 2002 493-507
The integrin 
vß8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-ß1
Dezhi Mu1,2,5,
Stephanie Cambier1,2,5,
Lars Fjellbirkeland1,2,5,
Jody L. Baron3,
John S. Munger4,
Hisaaki Kawakatsu5,
Dean Sheppard2,5,
V. Courtney Broaddus2,5 and
Stephen L. Nishimura1,2,5
1 Department of Pathology, University of California at San Francisco, San Francisco, CA 94143
2 University of California at San Francisco/Mt. Zion Cancer Center, University of California at San Francisco, San Francisco, CA 94143
3 Department of Microbiology and Immunology, University of California at San Francisco, San Francisco, CA 94143
4 Department of Medicine and Cell Biology, New York University, New York, NY 10016
5 The Lung Biology Center and Pulmonary Division, San Francisco General Hospital, San Francisco, CA 94110
Address correspondence to Stephen L. Nishimura, Bldg. 3, Rm. 207, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110. Tel.: (415) 206-5906. Fax: (415) 206-3765. E-mail: cdog{at}itsa.ucsf.edu
 |
Abstract
|
|---|
Întegrins, matrix metalloproteases (MMPs), and the cytokine TGF-ß have each been implicated in homeostatic cell behaviors such as cell growth and matrix remodeling. TGF-ß exists mainly in a latent state, and a major point of homeostatic control is the activation of TGF-ß. Because the latent domain of TGF-ß1 possesses an integrin binding motif (RGD), integrins have the potential to sequester latent TGF-ß (SLC) to the cell surface where TGF-ß activation could be locally controlled. Here, we show that SLC binds to 
vß8, an integrin expressed by normal epithelial and neuronal cells in vivo. This binding results in the membrane type 1 (MT1)-MMP–dependent release of active TGF-ß, which leads to autocrine and paracrine effects on cell growth and matrix production. These data elucidate a novel mechanism of cellular homeostasis achieved through the coordination of the activities of members of three major gene families involved in cell–matrix interactions.
Key Words: integrins; transforming growth factor ß; metalloprotease; cell cycle; homeostasis
|
Introduction
|
|---|
Cellular homeostasis is maintained in the organism through the correct responses to extra-, intra-, and intercellular signals (Potter, 1974). Imbalances in these signals can result in disruption of cellular homeostasis, leading to changes in cell mass and/or tissue organization. The cellular homeostatic machinery consists of secreted, cell surface, and intracellular molecules that together maintain cellular differentiation and the balance between quiescence and entry into the cell cycle (Lord, 1988). Homeostasis is regulated through the control of cell proliferation mediated through cell–extracellular matrix interactions in concert with growth-promoting and inhibitory cytokines (Giancotti, 1997; Schwartz, 1997). A growth inhibitory cytokine of particular importance in tissue homeostasis is the multifunctional cytokine TGF-ß (Lord, 1988). The important role of TGF-ß in homeostasis is illustrated by the fact that TGF-ß1–deficient mice develop epithelial hyperplasias (in addition to lethal multiorgan inflammation) within weeks after birth (Shull et al., 1992; Crawford et al., 1998).
TGF-ß1 is normally maintained in a latent or inactive state by the noncovalent association of the bioactive peptide of TGF-ß1 with its NH2-terminal propeptide, latency-associated peptide (LAP)*-ß1 (Munger et al., 1997). Therefore, normal TGF-ß function is thought to be largely controlled by its activation from the latent state, a process that is not understood completely (Munger et al., 1999). However, recent evidence suggests that cell surface molecules or secreted extracellular molecules can activate TGF-ß. Specifically, the integrin vß6 and the secreted extracellular matrix molecule thrombospondin (TSP)-1 have been implicated in activation of TGF-ß1 through nonproteolytic mechanisms (Crawford et al., 1998; Munger et al., 1999). In addition, plasmin or the cell surface localization of matrix metalloprotease MMP-9 by CD44 has been proposed to lead to activation of TGF-ß through proteolytic degradation of LAP-ß1 and LAP-ß2, respectively (Lyons et al., 1990; Yu and Stamenkovic, 2000). Although these mechanisms may be important to activation of TGF-ß, particularly in response to injury (Jirtle et al., 1991; Munger et al., 1999; Murphy-Ullrich and Poczatek, 2000) or during neoplastic progression (Yu and Stamenkovic, 2000), they individually do not explain the activation of TGF-ß1 in normal tissues. Indeed, mice deficient in TSP-1 (Crawford et al., 1998), plasminogen (Bugge et al., 1995), CD44 (Protin et al., 1999), or vß6 (Munger et al., 1999) are all born viable and are able to reproduce, in marked contrast to the uniform lethality of TGF-ß1–null mice (Shull et al., 1992).
The propeptide of TGF-ß1, LAP-ß1, contains an RGD motif that is recognized by a subset of integrins sharing in common the v integrin subunit (Munger et al., 1998). Thus, three of the five v integrins, vß1, vß5, and vß6, have been shown to bind to LAP-ß1, and of these only vß6 can mediate TGF-ß activation (Munger et al., 1998, 1999). Recently, evidence suggests that vß6-mediated activation of TGF-ß1 plays an important role in response to injury (Munger et al., 1999). Of the two remaining v integrins, vß3 does not bind to LAP-ß1 or mediate activation of TGF-ß1 (Munger et al., 1998), and vß8 has not been investigated since, until recently, a system has not been available to study its function (Cambier et al., 2000). The vß8 integrin is of particular interest, since it has been identified recently as an epithelial growth inhibitory molecule (Cambier et al., 2000). vß8 is expressed in the normal human airway epithelium but is lost in its malignant counterpart, suggesting a role in epithelial homeostasis (Cambier et al., 2000). Furthermore, heterologous expression of vß8 inhibits lung carcinoma cell growth both in vivo and in vitro (Cambier et al., 2000). Since vß8 and TGF-ß1 are coexpressed in normal tissues, such as the human airway (Crawford et al., 1998; Cambier et al., 2000), we considered the possibility that vß8 may participate in the maintenance of airway homeostasis through activation of TGF-ß.
In this article, we demonstrate a novel mechanism of cell growth regulation mediated by activation of TGF-ß1 via the integrin vß8. We show that vß8 can bind LAP-ß1 and that the consequence of this interaction is activation of TGF-ß1. This mechanism of activation of TGF-ß1 differs from other reported mechanisms because it is regulated through the coordinated interactions of integrins, TGF-ß, and MMPs on the cell surface. Furthermore, we show that when lung cancer cells are reconstituted with vß8, which is normally present on the epithelial cells from which they are derived, growth is now inhibited by TGF-ß1. These data provide novel insights into the mechanisms underlying cellular homeostasis.
|
Results
|
|---|
The integrin vß8 binds with high affinity to the RGD site of recombinant LAP-ß1
To determine if vß8 can bind to the RGD-containing LAP-ß1, we performed affinity chromatography using surface radiolabeled vß8 and immobilized LAP-ß1 (Fig. 1 a). Two bands of the appropriate kD for the v and ß8 subunits (150 and 90 kD, respectively) bound to immobilized LAP-ß1 in a divalent cation-dependent fashion as shown by elution with EDTA (Fig. 1 a, lanes 4–8). This binding was also dependent on the RGD sequence of LAP-ß1 as demonstrated by the inability of RGE (Fig. 1 a, lanes 1'–3') and the ability of RGD to elute vß8 (Fig. 1 a, lanes 4'–7'). The identity of the v and ß8 subunits in the elution fractions was confirmed by immunoprecipitation (Fig. 1 b). Anti-ß8 antibodies immunoprecipitated 150- and 90-kD bands from the RGD and EDTA elution fractions, which comigrated exactly with the two bands immunoprecipitated with anti-v and anti-ß8 antibodies from cell lysates (Fig. 1 b, RGD, EDTA, and LYSATE). Immunoprecipitations of the elution fractions using antibodies to the other RGD binding integrins present on HT1080 cells, namely vß5 and 5ß1, failed to detect any proteins (unpublished data). To measure the relative ability of truncated vß8 to bind to LAP-ß1 and vitronectin (VN), the only other known ligand for vß8 (Nishimura et al., 1994), we developed solid phase binding assays for vß8–ligand interactions using alkaline phosphatase (AP)-tagged vß8 (AP-vß8). The ability of AP-vß8 to bind to immobilized LAP-ß1 was confirmed by metabolic labeling and affinity chromatography (Fig. 1 c). Two bands of the appropriate molecular weight for the truncated v (140 kD) and ß8-AP (130 kD) subunits were eluted by RGD peptide (Fig. 1 c). No other metabolically labeled proteins from the cell supernatants were shown to bind to LAP-ß1 by this method (Fig. 1 c). In solid phase assays, considerably more AP-vß8 bound to wells coated with LAP-ß1 (10 µg/ml) than to wells coated with VN (100 µg/ml) (Fig. 1 d). AP-vß8 did not bind to a mutant form of LAP (LAP [RGE]) with a single amino acid substitution in the integrin recognition sequence (Fig. 1 d) and was completely eluted by either RGD (1 mg/ml) or EDTA (10 mM) (unpublished data). Furthermore, vß8 binding was almost completely inhibited by the monoclonal antibody 37E1, specific to ß8 (Fig. 1 d). The affinity of AP-vß8 for LAP-ß1–Sepharose was determined by saturation binding experiments. AP-vß8 bound to LAP-ß1 with high affinity (Kd 13 pM) with binding saturation reached at 
50% ligand occupancy (Fig. 1 e, Bmax: 0.5 fM/1.0 fM LAP-ß1). Scatchard analysis revealed a single high affinity state of AP-vß8, consistent with other reports that secreted v integrins are expressed in a constitutively active affinity state (Nishimura et al., 1994; Weinacker et al., 1994). In contrast to the high affinity of AP-vß8 for LAP-ß1, the affinity of AP-vß8 for VN, the only other known ligand for vß8 (Nishimura et al., 1994), was too low to be determined using this assay (unpublished data). Thus, vß8 binds preferentially to LAP-ß1 with high affinity, and this binding is both RGD and divalent cation dependent.
View larger version (39K):
[in this window]
[in a new window]
|
Figure 1. vß8 binds to LAP-ß1 in an RGD- and cation-dependent fashion. (a) N-octylglucoside lysates from 125I-cell surface-labeled ß8-expressing HT1080 cells (1 ml) were passed over two identical LAP-ß1–Sepharose columns (1 ml) and washed with 12 ml of wash buffer (shown in lanes 1, 2, and 3 are the 4th, 11th and 12th wash fractions). One column was eluted with 1-ml fractions containing 10 mM EDTA (fractions 4–8), and the other column was eluted with 1-ml fractions containing 1 mg/ml GRGESNK (lanes 1'–3') or 1 mg/ml GRGDSNK (lanes 4'–7'). Samples were resolved by 7.5% SDS-PAGE under nonreducing conditions and visualized by autoradiography. (b) EDTA and RGD elution fractions were immunoprecipitated with anti-ß8 (14E5) and compared with anti-v (L230) and anti-ß8 (14E5) immunoprecipitations from cell lysates. The migration of the MW markers is shown on the left, and the expected migration of the v (150 kD) and ß8 (90 kD) subunits is shown on the right. Samples were resolved by 7.5% SDS-PAGE under nonreducing conditions and visualized by autoradiography. (c) 35S metabolically labeled, (Translabel and ICN Biomedicals) truncated secreted vß8-AP fusion protein was applied to a 0.5-ml column of LAP-ß1–Sepharose, washed sequentially with six fractions of wash buffer (lane 1, last wash fraction), and then eluted with 1 mg/ml GRGDSPK (lanes 2–6). On the left are the migrations of the MW markers, and on the right are the expected migrations of the truncated v (140 kD) and the truncated ß8-AP (130 kD) subunits. Samples were resolved by 10% SDS-PAGE under nonreducing conditions and visualized by autoradiography. (d) Supernatant containing secreted truncated vß8 with a COOH-terminal AP tag (AP-vß8) was applied to wells of a 96-well plate coated with either LAP-ß1 (10 µg/ml) containing the RGD or the RGE binding motif or with VN (100 µg/ml) in the presence or absence of an anti-ß8–blocking monoclonal antibody, 37E1. Specific binding was determined colorimetrically. An asterisk indicates increased binding of receptor to LAP (RGD) compared with antibody-treated or LAP (RGE) controls (p < 0.001). (e) Binding affinity of vß8 for LAP-ß1 was determined using concentrated AP-vß8 and LAP-ß1–Sepharose (1fM LAP-ß1/bead). Receptor concentration was determined using purified placental AP (Applied Biosystems) as a standard. Dilutions of AP-ß8 were incubated under equilibrium-binding conditions (overnight at 4°C) with 10 µl LAP-ß1–Sepharose. Bound receptor was determined by luminescence using a CSPD substrate (Tropix; Applied Biosystems). (f) Adhesion of ß8-expressing versus mock-transduced HT1080 cells to LAP-ß1 (LAP) and SLC-coated wells of a 96-well plate. Cells (5 x 104/well) were applied to each well, and after incubation for 1 h at 37°C unbound cells were removed by centrifugation. Absorbance (A595) after staining with Crystal violet is shown on the right. *p < 0.05; **p < 0.01.
| |
To determine if vß8 expressed on the cell surface could bind latent TGF-ß (SLC) under physiologic conditions, we performed cell adhesion assays using both SLC and LAP-ß1 as immobilized ligands. ß8-expressing HT1080 cells bound significantly better to SLC than to LAP-ß1 at the 1.0 and 2.5 µg/ml coating concentrations, whereas mock-transduced HT1080 cells did not bind at all (Fig. 1 f). The reason for the increase in the vß8-dependent cell adhesion to SLC compared with LAP-ß1 is unclear. However, it is likely that the presence of the mature TGF-ß1 peptide in SLC results in conformational differences between SLC and LAP-ß1, which could affect either receptor binding, stability, or coating efficiency. Thus, we show that SLC is the first and only known ligand capable of supporting stable vß8-mediated adhesion, since VN, the only other known vß8 ligand, does not support stable vß8-mediated adhesion (Nishimura et al., 1994).
The integrin vß8 mediates activation of SLC
To determine the functional consequence of LAP–vß8 interactions, we assessed the ability of vß8 to activate the endogenous SLC present in coculture systems. These systems consisted of ß8-expressing or mock-transduced cells cocultured with reporter cell lines (TMLC [Abe et al., 1994] or HepG2-[SBE]4-Lux [Jonk et al., 1998]) responsive to active TGF-ß. We found that the TMLC reporter cell system was a more specific bioassay system for TGF-ß activity than the HepG2- (SBE)4-Lux system and was therefore used for most of these studies. The TMLC system consists of mink lung epithelial cells stably transfected with a TGF-ß responsive fragment of the plasminogen activator inhibitor-1 promoter driving the luciferase gene (Abe et al., 1994). TMLC cells are highly responsive to TGF-ß and produce a very low background of TGF-ß activation. TMLC cells can thus be used in coculture with other cell lines or cell-free fractions to test for the presence of active TGF-ß using luminescence as a readout.
In the HT1080, SW480, and H647 cell lines, heterologous expression of ß8 had either no effect or a slight effect on the cell surface expression of the other integrin ß subunits known to interact with the RGD motif (Table I). The only significant differences were a reduction of surface expression of the ß5 subunit in ß8-transduced compared with mock-transduced HT1080 and SW480 cells. It is possible that these slight reductions in surface expression of vß5- on ß8-expressing HT1080 and SW480 cells could potentially reduce the magnitude of the ß8 effect on adhesion to LAP-ß1 or influence the activation of TGF-ß. However, this is unlikely, since the vß5 integrin binds very weakly and does not mediate adhesion to SLC (Fig. 1 f, mock).
View larger version (30K):
[in this window]
[in a new window]
|
Figure 2. Cell surface expression of vß8 mediates activation of TGF-ß. HT1080 (a), MvLu (b), SW480 (c), and H647 (d) cells either ß8-transduced or mock-transduced were cocultured with TMLC reporter cells in the presence or absence of a neutralizing anti-ß8 antibody (37E1) or pan–TGF-ß neutralizing antibody (1D11). Relative luciferase units represent arbitrary units minus the TMLC background. Asterisks indicate increased luciferase activity of untreated ß8-expressing cells compared with antibody-treated or mock controls. p < 0.001.
| |
Heterologous expression of vß8 mediated activation of TGF-ß in HT1080, SW480, and MvLu cells as determined by coculture with either TMLC (Fig. 2, a–d) or HepG2-(SBE)4-Lux reporter cells (unpublished data). TGF-ß activation was specifically mediated by vß8, since it was substantially inhibited by the anti-ß8 antibody, 37E1 (Fig. 2, a–c). The other RGD binding integrin heterodimers normally present in SW480, HT1080, and MvLu cells (Table I) did not mediate significant activation of TGF-ß because mock-transduced cells did not activate TGF-ß (Fig. 2, a–c). However, H647 cells, which normally express vß6 (Table I), activated TGF-ß (note the higher activation in mock H647 cells than in other cell lines in Fig. 2 d). This activation in mock-transduced H647 cells could be completely inhibited by antibodies to ß6; activation in ß8-expressing H647 cells could be completely inhibited by a combination of ß8 and ß6 antibodies (unpublished data). These data demonstrate that when ß8 and ß6 are coexpressed the resulting TGF-ß activation is additive. The TGF-ß isoform that was primarily responsible for TGF-ß activation in our system was TGF-ß1, since TGF-ß1 isoform-specific antibodies inhibited 80–90% of the activation in SW480, HT1080, MvLu, and H647 cells, whereas TGF-ß2 and TGF-ß3 isoform-specific antibodies had minimal effect (unpublished data).
Evidence that the ß8-cytoplasmic domain is not required for vß8-mediated activation of TGF-ß
The mechanism of integrin vß6-mediated activation of TGF-ß is likely to depend on the transduction of mechanical forces to induce conformational changes of SLC (Munger et al., 1999). Thus, vß6-mediated activation of TGF-ß is critically dependent on specific sequences within the ß6 cytoplasmic domain (Munger et al., 1999). However, the ß8 cytoplasmic domain has no similarity with the cytoplasmic domain of ß6 or any other integrin ß subunit (Moyle et al., 1991). We have shown previously that the ß8 cytoplasmic domain is incapable of linking to the cytoskeleton to stabilize cell adhesion (Nishimura et al., 1994; Cambier et al., 2000). Therefore, we sought to determine whether the ß8 cytoplasmic domain would influence interactions with LAP-ß1. We expressed and tested a series of ß8 cytoplasmic deletion mutants (Fig. 3, a–c) for their ability to mediate adhesion to LAP-ß1 (Fig. 3 d) and to activate TGF-ß (Fig. 3, e and f). The complete (TM) cytoplasmic deletion mutant was expressed at sixfold lower surface levels than the partial (759) cytoplasmic deletion mutant or the wild-type (FL) subunit (Fig. 3 c). Low levels of surface expression of the TM mutant could be due to a decreased ability to associate with the v subunit, alterations in intracellular transport, or increased degradation. SW480 cells expressing sixfold lower surface levels of the TM mutant compared with SW480 cells expressing the 759 mutant or the FL subunit adhered only slightly less well to LAP-ß1 (TM adhesion saturation reached at 5 compared with 2.5 µg/ml coating concentration for 759 and FL) (Fig. 3 d). Unlike ß6-transduced SW480 cells (Munger et al., 1999), SW480 cells transduced with full-length or mutant forms of ß8 failed to spread appreciably on LAP-ß1 (unpublished data).
View larger version (55K):
[in this window]
[in a new window]
|
Figure 3. The cytoplasmic domain of ß8 is not required for cell adhesion to LAP-ß1 or activation of TGF-ß. (a) Construction of ß8 subunit cytoplasmic truncation mutants. The full-length ß8 (FL) subunit, a partial truncation mutant missing the COOH-terminal 11 amino acids (759), and a complete truncation mutant missing the complete ß8 cytoplasmic domain (TM) were assembled by PCR mutagenesis and subcloned into retroviral vectors. (b) Immunoprecipitation analysis of surface-labeled SW480 cells, expressing FL, 759, TM, or retroviral backbone (mock) using an anti-ß8 monoclonal antibody (37E1). The results demonstrate the presence and dimerization with the v subunit on the cell surface and absence of the cytoplasmic domain in the TM construct. Biotinylated proteins were detected by Western blotting. Note that 37E1 is specific to vß8 because the two immunoprecipitated bands, corresponding to the v subunit or the ß8 subunit, were not seen in mock-transduced cells. Also, note that the TM construct was expressed at lower levels on the cell surface compared with 759 and FL. To determine the absence of the intracellular epitope in TM-expressing cells, cell lysates were immunoprecipitated with 37E1 and analyzed by Western blotting using a polyclonal anti-ß8 antibody directed against the entire ß8 cytoplasmic domain. In b (bottom), note that no signal for ß8 is seen in the ß8 immunoprecipitates of the truncation mutant (TM), indicating absence of the ß8 cytoplasmic domain. (c) FACS® of cytoplasmic deletion mutants (TM and 759) versus the wild type (FL) ß8 subunit expressed in SW480 cells. Note the TM mutant is expressed at sixfold lower levels than the 759 or FL constructs. Histograms using arbitrary fluorescence units are shown. (d) Adhesion assays of SW480 cells expressing ß8 truncation mutants demonstrate that the cytoplasmic domain of ß8 is not required for adhesion to LAP-ß1. Note that despite lower levels of surface expression of the TM construct, all constructs bound well to LAP-ß1, whereas mock-transduced SW480 cells do not adhere to LAP-ß1. (e-f) Demonstration that the ß8 cytoplasmic domain is not required for activation of TGF-ß. SW480 or HT1080 cells expressing the wild-type or truncation mutants were cocultured with TMLC reporter cells in the presence or absence of anti-ß8 (37E1) or pan anti–TGF-ß (1D11). Relative luciferase units are shown. Single and double asterisks indicate increased luciferase activity of untreated wild-type or mutant ß8-expressing cells compared with antibody-treated or mock controls (*p < 0.01; **p < 0.001).
| |
SW480 and HT1080 cells expressing the FL subunit and the TM and 759 mutants also mediated significant activation of TGF-ß compared with mock-transduced cells (Fig. 3, d and e). Concordant with sixfold lower levels of surface expression, SW480 cells expressing the TM mutant did not activate TGF-ß1 as well as cells expressing either 759 mutant or the FL subunit (Fig. 3 b). However, cells expressing the TM mutant adhered to LAP-ß1 and activated TGF-ß only twofold less than the 759 or FL constructs (Figs. 3, c–e). This discordance may be due to dependence on the ligand concentration rather than the receptor number in these assays (e.g., saturation). Alternatively, it is possible that the cytoplasmic domain of ß8 actually plays a negative regulatory role in vß8–TGF-ß interactions. This latter possibility is consistent with the hypothesis that the divergent cytoplasmic domain of ß8 plays a general inhibitory role (Cambier et al., 2000).
Together these findings suggest that the cytoplasmic domain of ß8 is not required for either adhesion to LAP-ß1 or activation of TGF-ß. Thus, it is likely that the mechanism of vß8-mediated activation of TGF-ß1 is distinct from the mechanosignal transduction mechanism described for vß6 (Munger et al., 1999).
vß8-mediated activation of TGF-ß requires localization to the cell surface and metalloprotease activity
The fact that the cytoplasmic domain of ß8 is not required for activation of TGF-ß1 suggests that vß8-mediated activation of TGF-ß might be regulated extracellularly either in the extracellular space or on the cell surface. To test these possibilities, we first tested the ability of soluble secreted vß8 to activate TGF-ß. We found no evidence, using a variety of receptor preparations (supernatant containing secreted vß8 or lectin- or antibody-purified receptor), that soluble secreted vß8 could activate TGF-ß (with supernatant containing secreted vß8 or media control; relative luciferase units: vß8, 7.8 ± 0.1; media control, 11.8 ± 1.2, p > 0.05). This suggests that cell surface localization of vß8 is required for TGF-ß activation.
Because proteolytic cleavage is a common mechanism of regulating cytokine activity, we tested the ability of protease inhibitors to block vß8-mediated activation of TGF-ß. GM6001, a member of the hydroxamate class of protease inhibitors specific to metalloproteases, but not a control peptide lacking the metal-binding hydroxamate modification (C1006), significantly blocked vß8-mediated TGF-ß activation in SW480 (Fig. 4 a) and HT1080 cells (59.0 ± 10.0% inhibition using 5 µM GM6001; 0.0 ± 0.9% using 5 µM C1006, p < 0.01). This inhibition was specific to vß8 because vß6-mediated activation of TGF-ß was not inhibited by GM6001 (5 µM) in SW480 cells (Fig. 4 a) or HT1080 cells (1.0 ± 0.1% inhibition, p > 0.05). Finally, other peptide and chemical inhibitors of aspartyl (pepstatin A), serine (PMSF, CK-23, aprotinin, and leupeptin), or cysteine (leupeptin and E64) proteases had no effect on vß8-mediated activation of TGF-ß1 when used at the maximal nontoxic doses (Fig. 4 b). Together these data suggest a novel mechanism of vß8-mediated activation of TGF-ß1 requiring both the cell surface and metalloprotease activity.
Cell surface expression of vß8 is associated with liberation of active TGF-ß
All previously described mechanisms of cell-associated protease-dependent activation of TGF-ß involve liberation of active TGF-ß from SLC, presumably as a result of degradation of LAP (Lyons et al., 1988, 1990; Abe et al., 1998). Therefore, we hypothesized that if a cell surface proteolytic event was involved in vß8- but not vß6-mediated activation of TGF-ß then active TGF-ß should be released by ß8- but not ß6-expressing cells into the cell culture supernatant. To test this hypothesis, we assayed the supernatants of ß8-expressing, ß6-expressing, or mock-transduced HT1080 cells for active TGF-ß. In HT1080 cells, ß8 was expressed at lower surface levels than ß6 (Fig. 5 a). Concordant with lower expression levels, vß8-expressing cells activated less TGF-ß than vß6-expressing cells in coculture assays (Fig. 5 b). However, when supernatants of ß8-expressing, ß6-expressing, and mock-transduced HT1080 cells were tested only supernatant from ß8-expressing cells contained a significant amount of active TGF-ß (Fig. 5 c). The presence of active TGF-ß in the cell supernatant of ß8-expressing cells was confirmed by inhibition with anti–TGF-ß antibodies (Fig. 5 c). Specificity was demonstrated by inhibition with anti-ß8 antibodies and by the relative lack of active TGF-ß in the supernatant of mock-transduced HT1080 cells (Fig. 5 c). Supernatant from ß6-expressing HT1080 cells also had a slight but insignificant (p > 0.05) increase in active TGF-ß compared with mock-transduced cells (Fig. 5 c). However, the presence of active TGF-ß in the cell supernatant of ß6-expressing cells was not ß6 specific, since it was not blocked by anti-ß6 antibodies. The presence of active TGF-ß in the supernatant of this ß6-expressing cell pool is likely due to random differences in integrin-independent release of active TGF-ß by different cell pools, but we cannot exclude that it is due to an indirect effect of ß6 expression in HT1080 cells. Consistent with the above HT1080 cell data, we also found that a small but significant amount of TGF-ß1 was present in the cell culture supernatant of ß8-expressing SW480 cells (relative luciferase units, 0.92 ± 0.23; +37E1, 0.26 ± 0.08; p < 0.05). In summary, active TGF-ß is released into the supernatant of ß8-expressing cells through a ß8-dependent mechanism, suggesting that vß8 binds SLC to the cell surface, which facilitates the metalloprotease-dependent release of active TGF-ß into the cell supernatant.
View larger version (29K):
[in this window]
[in a new window]
|
Figure 5. Active TGF-ß is liberated into the supernatants of vß8-expressing cells. (a) Expression of ß8 and ß6 on the cell surface of ß8-, ß6-, and mock-transduced HT1080 cells using monoclonal antibodies specific for the ß8 (14E5) or ß6 (E7P6) integrin subunits. (b) Comparison of ß8- and ß6-mediated activation of TGF-ß in cocultures with TMLC reporter cells. (c) Detection of active TGF-ß liberated into the supernatant from ß8-expressing but not ß6- or mock-transduced HT1080 cells. Neutralizing antibodies to TGF-ß were 1D11, or to ß8 or ß6 were 37E1 or 10D5, respectively. Relative luciferase units are shown in b and c. The asterisk indicates increased luciferase activity from supernatants of untreated ß8-expressing cells compared with antibody-treated or mock controls (p < 0.01).
| |
Expression of membrane-type 1–MMP is sufficient to support vß8-mediated activation of TGF-ß
In the course of screening cell lines for this study, we identified one squamous lung carcinoma cell line, H1264, that expressed a low level of vß8 on the cell surface but did not activate TGF-ß. The inability of H1264 cells to activate TGF-ß was not due to low expression levels of vß8, since overexpression of ß8 by retroviral transduction did not rescue activation (relative luciferase units; ß8-transduced, 3.0 ± 0.3; +37E1, 2.2 ± 0.5; mock-transduced, 3.0 ± 0.4; ±37E1, 2.6 ± 0.2). Since our current findings suggested that cell surface expression of a metalloprotease cofactor was likely involved in vß8-mediated activation of TGF-ß, we used H1264 cells to facilitate the identification of the specific metalloprotease(s) involved in vß8-mediated activation of TGF-ß. Thus, we generated a metalloprotease expression profile of H1264 cells and compared it to profiles of the other tumor cell lines used in this study. We concentrated on metalloproteases known to localize to the cell surface (MMP-2 [Brooks et al., 1996], MMP-7 [Yu and Woessner, 2000], MMP-9 [Yu and Stamenkovic, 1999], membrane-type 1 [MT1]-MMP MMP [Sato et al., 1994], and a disintegrin and a metalloprotease domain [ADAM]-9, -10, and -17 [Primakoff and Myles, 2000]). Using reverse transcriptase (RT)–PCR (Fig. 6 a) and gelatin zymography (unpublished data), we found that the only metalloprotease that was deficient in H1264 cells, relative to the other tumor cell lines used in this study, was MT1-MMP. To reconstitute MT1-MMP expression in H1264 cells, we introduced either a full-length (MT1-MMP) or a transmembrane-deleted secreted form of MT1-MMP (
MT1-MMP). Expression or lack of expression of MT1-MMP in transduced or mock-transduced H1264 cells was verified by immunoblotting (Fig. 6 b). Immunoblots revealed an appropriate 63-kD band in cell lysates from MT1-MMP–transduced H1264 cells (Fig. 6 b) and a 54-kD band from the supernatant of MT1-MMP–transduced cells (Fig. 6 b). The absence of any bands in mock-transduced cells confirmed the absence of MT1-MMP in the parental H1264 cell line (Fig. 6 b). Reconstituted MT1-MMP was active in H1264 cells as determined by the ability of MT1-MMP–transduced but not MT1-MMP–transduced or mock-transduced H1264 cells to cleave pro–MMP-2 to its fully active (59 kD) form (Fig. 6 c). Secreted MT1-MMP possessed gelatinolytic activity as determined by zymography (unpublished data).
H1264 cells transduced with either MT1-MMP, MT1-MMP, or vector alone (mock) underwent a second transduction to overexpress similar levels of vß8 as determined by flow cytometry using the anti-ß8 antibody, 14E5 (Fig. 7 a), or SN1 (unpublished data). For ß8-overexpressing H1264 cells, only those transduced with MT1-MMP and not MT1-MMP or vector alone (mock) were able to support activation of TGF-ß (Fig. 7 b). H1264 cells transduced with MT1-MMP alone supported a low level of vß8-mediated activation of TGF-ß (relative luciferase units; no monoclonal antibody, 2.7 ± 0.2; +37E1, 1.3 ± 0.0; +1D11, -0.3 ± 0.01), which is consistent with their lower levels of surface expression of vß8. A significant portion of the TGF-ß activation was specific to ß8 and to metalloproteases because it was inhibited by anti-ß8 antibodies (37E1), TIMP-2, and GM6001. 37E1, TIMP-2, and GM6001 were less efficient than the pan–TGF-ß antibody (1D11) in inhibiting TGF-ß activity. TIMP-2, a relatively specific inhibitor of MT1-MMP (Brew et al., 2000), inhibited TGF-ß activation equally well as 37E1 (Fig. 7 c). The inability to completely block the ß8-, MT1-MMP–dependent activation of TGF-ß with anti-ß8 antibodies and MMP inhibitors is likely due to a combination of factors: antibody efficacy, steric hindrance on the cell surface (Atkinson et al., 2001) and/or the high heterologous expression levels of both ß8 and MT1-MMP.
View larger version (35K):
[in this window]
[in a new window]
|
Figure 7. vß8 mediates activation of TGF-ß in ß8-overexpressing H1264 cells reconstituted with MT1-MMP activity. (a) Flow cytometry of ß8-transduced MT1-MMP, MT1-MMP, or mock-transduced H1264 cells demonstrates equivalent levels of surface expression of ß8 using an anti-ß8 antibody (14E5). Histograms using arbitrary units are shown. (b) ß8-overexpressing H1264 cells transduced with either MT1-MMP, MT1-MMP, or the retroviral vector alone (mock) (1.6 x 104) were cocultured with TMLC (1.6 x 104) reporter cells in the presence or absence of inhibitors: anti-ß8 (37E1), control peptide (C1006), GM6001, or the pan–TGF-ß1 antibody (1D11). Asterisks indicate significantly different than untreated MT1-MMP–expressing cells. (c) The endogenous inhibitor TIMP-2 but not TIMP-1 inhibits vß8-mediated activation of TGF-ß in H1264s cells. ß8-overexpressing, MT1-MMP–expressing H1264s cells were cocultured with TMLC in the presence or absence of TIMP-1 (1 µg/ml), TIMP-2 (1 µg/ml), GM6001 (5 µM), anti-ß8 (37E1), or pan-TGF-ß1 (1D11). Relative luciferase units are shown (light units of cocultured cells in the presence or absence of inhibitors minus light units of TMLC cells alone) in b and c. Negative luciferase values were occasionally observed due to a small background of TGF-ß activation by the TMLC cells. Single and double asterisks indicate treated cells compared with untreated cells (*p < 0.01; **p < 0.001).
| |
vß8 and MT1-MMP colocalize in substrate contacts
Our cell biologic and biochemical data indicated that vß8 and MT1-MMP were likely to associate on the cell surface. Thus, we hypothesized that upon ligation with LAP-ß1, vß8 and MT1-MMP would cocluster in membrane complexes. To address this hypothesis, we expressed an MT1-MMP fusion construct with a COOH-terminal green fluorescent protein (GFP) tag. The purpose of the GFP tag was to obviate the use of available commercial anti–MT1-MMP antibodies, which we found unsuitable for immunocytochemistry (unpublished data). MT1-MMP–GFP was expressed on the cell surface of ß8-expressing HT1080 cells as determined by surface labeling followed by immunoprecipitation with anti-GFP antibodies. Anti-GFP antibodies immunoprecipitated two bands from MT1-MMP–GFP–expressing cells, the upper band representing the catalytically active form of MT1-MMP–GFP and the lower band the degraded form, lacking the catalytic domain (Overall et al., 2000) (Fig. 8 a, top). Furthermore, MT1-MMP–GFP was found to be functionally active as determined by potentiation of the zymographic conversion of pro-MMP2 to active MMP2 (Fig. 8 a, bottom).
View larger version (44K):
[in this window]
[in a new window]
|
Figure 8. vß8 and MT1-MMP colocalize in substrate contacts. (a, top) Immunoprecipitation of MT1-MMP–GFP from 125I cell surface-labeled MT1-MMP–GFP–expressing HT1080 cells. The catalytically active 90-kD MT1-MMP–GFP fusion protein (asterisk) was immunoprecipitated with anti-GFP antibodies from MT1-MMP–GFP–expressing HT1080 ß8 cells but not mock-transduced HT1080 ß8 cells. The 70-kD MT1-MMP–GFP band represents a catalytically inactive degradation product. (a, bottom) Gelatin zymography of supernatants from MT1-MMP–GFP–transduced or mock-transduced HT1080 ß8 cells. The migration of Pro (Pro-) and active (Act.-) forms of MMP-2 are shown. (b–m) Confocal images of immunofluorescence microscopy. ß8-expressing, MT1-MMP–GFP–expressing HT1080 cells (b–d and k–m); ß8-expressing HT1080 cells (e–g); GFP-expressing HT1080 cells (h–j). Cells were allowed to attach 4 h to LAP-ß1 (10 µg/ml coating concentration)-coated slides. After fixation and permeabilization, colocalization of ß8 and GFP was determined using polyclonal anti-ß8 and monoclonal anti-GFP antibodies. Pseudocolored confocal images of ß8 (red) and GFP (green) staining taken in the plane of the substrate are shown. Bar, 7.5 µM.
| |
We determined using confocal microscopy that ß8 and MT1-MMP–GFP exactly colocalized in discrete clusters in the plane of an LAP-ß1 substrate using anti-ß8 and GFP antibodies (Fig. 8, b–d). The localization of ß8 to these substrate contacts was not due to "bleed-over" of the MT1-MMP–GFP signal, since the GFP signal was not intense enough to visualize without staining with an anti-GFP antibody and ß8 localization was seen in ß8-expressing HT1080 cells not transduced with MT1-MMP–GFP (Fig. 8, e–g). As expected, antibodies against the v subunit colocalized with antibodies against the ß8 subunit in these contacts when cells were plated on LAP-ß1 (unpublished data). Localization of ß8 was not dependent on MT1-MMP expression, since ß8 was found in substrate contacts in MT1-MMP–deficient ß8-expressing H1264 cells plated on an LAP-ß1 substrate (unpublished data). Localization of MT1-MMP–GFP to substrate contacts was not due to nonspecific accumulation of GFP or to a staining artifact, since no substrate contacts were found with anti-GFP antibodies in GFP-transduced non-ß8–expressing HT1080 cells plated on LAP-ß1 (Fig. 8, h–j). Localization of MT1-MMP to LAP-ß1 substrate contacts was dependent on ß8 expression, since no contacts were found in non-ß8–expressing, MT1-MMP–GFP–expressing HT1080 cells (unpublished data). Finally, the colocalization of ß8 and MT1-MMP to substrate contacts required ligand engagement, since no such contacts were found when ß8-, MT1-MMP–GFP expressing HT1080 cells were plated on an irrelevant ligand, collagen I (Fig. 8, k–m). In conclusion, ligation of vß8 with LAP-ß1 results in the specific colocalization of vß8 and MT1-MMP in substrate contacts, suggesting a biologically relevant and close physical interaction.
Overexpression of MT1-MMP is sufficient to cleave and inactivate LAP-ß1
To determine if proteolysis of LAP-ß1 could be a mechanism of vß8-mediated activation of TGF-ß, we incubated recombinant LAP-ß1 with ß8-overexpressing H1264 cells transduced with either MT1-MMP, MT1-MMP, or vector alone. After incubation of LAP-ß1 with mock or MT1-MMP–expressing H1264 cells, LAP-ß1 remained intact (32 kD). In contrast, we found that almost all of the LAP-ß1 incubated with MT1-MMP–expressing H1264 cells was smaller (26–28 kD) than intact LAP-ß1, suggesting proteolytic cleavage (Fig. 9 a, lane 4). LAP-ß1 cleavage was dependent on the metalloprotease activity of MT1-MMP, since the metalloprotease inhibitor GM6001 but not a control peptide C1006 completely blocked cleavage (Fig. 9 a, lanes 5 and 6). To determine if LAP-ß1 cleavage was also dependent on vß8, we developed a peptide based on the human LAP-ß1 sequence, which was a relatively specific inhibitor of vß8–LAP-ß1 interactions. In the H1264 system, the GRRGDLATIH peptide completely blocked vß8–LAP-ß1 interactions while having a minimal effect on the binding of other RGD-dependent integrins to VN or fibronectin (Fig. 9 b). Using these peptide inhibitors, we determined that LAP-ß1 cleavage was also dependent on vß8, since GRRGDLATIH but not the RGE mutant peptide inhibited LAP-ß1 cleavage (Fig. 9 c). Thus, in the H1264 cell system, vß8 and MT1-MMP together are required for LAP-ß1 cleavage. Finally, vß8-, MT1-MMP–dependent cleavage of LAP-ß1 is functionally relevant, since LAP-ß1, after cleavage, loses the ability to inhibit the function of the recombinant mature TGF-ß1 peptide (Fig. 9 d).
View larger version (33K):
[in this window]
[in a new window]
|
Figure 9. Cell surface-associated MT1-MMP cleaves and inactivates LAP-ß1. (a) LAP-ß1 is cleaved by incubation with ß8-overexpressing MT1-MMP but not MT1-MMP or mock-transduced H1264 cells. LAP-ß1 (10 µg/ml) was incubated overnight with either no cells (lane 1), mock-transduced ß8-overexpressing H1264 cells (lane 2), MT1-MMP transduced, ß8-overexpressing H1264 cells (lane 3), MT1-MMP transduced, ß8-overexpressing H1264 cells (lane 4), 500 µg/ml of control peptide (C1006; lane 5), or 500 µg/ml hydroxymate inhibitor GM6001 (lane 6). 20 ng of the input LAP-ß1 was resolved by 12.5% SDS-PAGE under reducing conditions. After immunoblotting with an anti-LAP antibody, the migration of the cleavage products calibrated to molecular weight standards (GIBCO BRL) is shown. Note that only LAP-ß1 incubated in the presence of MT1-MMP is cleaved and that this cleavage is blocked by GM6001. (b) The TGF-ß1 peptide GRRGDLATIH selectively inhibits vß8–LAP-ß1 function. Adhesion assay of ß8-overexpressing, MT1-MMP expressing H1264 cells (4 x 104) to LAP-ß1, VN, or fibronectin (FN) (10 µg/ml coating concentrations) in the presence or absence of 50 µg/ml of GRRGDLATIH. (c) LAP-ß1 cleavage by MT1-MMP–transduced, ß8-overexpressing H1264 cells is inhibited by GRRGDLATIH but not GRRGELATIH peptide (10 µg/ml). The degradation assay was performed and analyzed by immunoblotting as in a. No-cell control (lane 1); no-inhibitor control (lane 2); control GRRGELATIH peptide (lane 3); GRRGDLATIH peptide (lane 4). (d) LAP-ß1 is inactivated by ß8-overexpressing, MT1-MMP-expressing H1264 cells. LAP-ß1 (5 µg) incubated overnight with ß8-overexpressing, MT1-MMP-expressing or ß8-overexpressing, mock-transduced H1264 cells was added to TMLC reporter cells in the presence of recombinant TGF-ß1. As a control (white bars) TMLC reporter cells were incubated with only recombinant TGF-ß and no LAP-ß1. Relative luciferase units are shown. The asterisk indicates LAP-ß1 incubated with mock control cells is not cleaved and decreases TGF-ß activity compared with other groups (p < 0.05).
| |
TGF-ß activated by the integrin vß8 in human lung cancer xenografts results in growth inhibition and tumor fibrosis
To test the physiologic relevance of vß8-mediated activation of TGF-ß1, we employed the H647 lung carcinoma cell system, which we have described recently (Cambier et al., 2000). We employed this system because ß8 is expressed mainly by the basal cells of the human airway (Cambier et al., 2000), a cell type that is difficult to isolate in sufficient numbers for our studies and difficult to maintain in culture (Hicks et al., 1997). Because we have demonstrated recently that the growth of ß8-expressing H647 cells was inhibited relative to mock-transduced H647 cells (Cambier et al., 2000), we asked if TGF-ß might be a mediator of that growth inhibition. To address this question, we determined BrdU incorporation as a measure of DNA synthesis in ß8-expressing and in mock-transduced H647 cells. We determined that the growth of ß8-expressing H647 cells was potently inhibited relative to mock-transduced control cells as reflected by reduced BrdU incorporation (Fig. 10 a). In addition, since TGF-ß characteristically induces a cell cycle arrest late in G1 (Laiho et al., 1990) we studied the cell cycle defect in H647 cells. Nonsynchronized ß8-expressing H647 cells displayed a partial G1 arrest when compared with mock-transduced H647 cells (G1 fraction of ß8-expressing H647 cells, 62% ± 3%; mock-transduced H647 cells, 47 ± 3%, p < 0.05). Furthermore, we found that this ß8-dependent growth inhibition was also TGF-ß–dependent because it could be reversed by TGF-ß antibodies (Fig. 10 a) or by recombinant LAP-ß1 (for ß8-expressing H647 cells without LAP-ß1, G1 fraction, 61%; with LAP-ß1, 51%, in a representative experiment). Thus, TGF-ß is a mediator of ß8-induced growth inhibition in vitro.
To address if vß8 also mediated TGF-ß activation in vivo, we used ß8-expressing or mock-transduced H647 cells, which are tumorigenic in nude mice (Cambier et al., 2000). Using this system, we have found ß8-expressing tumors to be significantly smaller than their mock-transduced counterparts (Cambier et al., 2000). Because fibrosis is one of the histologic hallmarks of increased TGF-ß activity (Border and Noble, 1994), we examined ß8-expressing tumors histologically for evidence of fibrosis. We found that ß8-expressing tumors were not only smaller but were more fibrotic than tumors derived from mock-transduced cells (Fig. 10 b). To determine if the reduction in tumor size and the increase in stromal fibrosis were associated with increased active TGF-ß, we used the TMLC reporter cells to determine the active and SLC activities associated with ß8-expressing and mock-transduced H647 tumor xenografts. Using this bioassay, there was a significant increase in the amount of active TGF-ß present in the aqueous fraction of ß8-expressing tumors relative to control tumors (Fig. 10 c). In contrast, the latent component of TGF-ß did not differ between tumors derived from ß8-expressing or mock-transduced H647 cells (Fig. 10 c). Thus, in vivo vß8 can liberate physiologic levels of TGF-ß activity. Moreover, these data suggest that in normal tissues vß8-mediated activation of TGF-ß must be more tightly regulated than in the tumor xenograft model, since fibrosis is only associated with pathologic states (Blobe et al., 2000).
|
Discussion
|
|---|
We have found previously that the integrin vß8 inhibits epithelial cell growth (Cambier et al., 2000). Furthermore, vß8 is expressed in either quiescent cells or cells with a low rate of turnover (Nishimura et al., 1998; Cambier et al., 2000) and is lost in the process of neoplastic transformation (Cambier et al., 2000). These findings led us to hypothesize that ß8 plays a role in the homeostatic control of normal tissues. In support of this hypothesis, we now demonstrate that the integrin vß8 mediates growth inhibition through a novel mechanism of activation of TGF-ß1, a cytokine with a central role in homeostatic cellular processes (Blobe et al., 2000).
Two molecular mechanisms have been proposed that may lead to the activation of TGF-ß1: conformational change leading to activation of the SLC complex (Crawford et al., 1998; Munger et al., 1999) or proteolysis of LAP-ß1 leading to the release of active TGF-ß1 (Munger et al., 1997; Yu and Stamenkovic, 2000). Our data demonstrate that a mechanism of conformational change leading to activation of TGF-ß, as proposed for the vß6 integrin (Munger et al., 1999) or TSP-1 (Crawford et al., 1998), is not responsible for vß8-mediated activation of TGF-ß1. Specifically, vß8-mediated activation of SLC does not require the ß8 cytoplasmic domain in contrast to the mechanism of vß6-mediated activation of TGF-ß, which requires the ß6-cytoplasmic domain (Munger et al., 1999). Furthermore, vß8 is unlikely to bind directly or indirectly to LAP-ß1 through a TSP-1–dependent mechanism because vß8 lacks the defined TSP-1 binding site for LAP-ß1 (Crawford et al., 1998) and vß8 does not bind to TSP-1 (unpublished data). Moreover, unlike secreted TSP-1 (Crawford et al., 1998) secreted vß8 cannot activate TGF-ß1. Thus, the mechanism by which vß8 activates TGF-ß1 is not dependent on conformational changes, resulting from "inside-out" signal transduction as mediated by the ß6 cytoplasmic domain (Munger et al., 1999) or direct physical interaction as mediated by TSP-1(Crawford et al., 1998).
Our findings support a biologically relevant mechanism whereby SLC binds with high affinity to vß8 on the cell surface, which results in the metalloprotease-dependent release of active TGF-ß. Evidence to support this mechanism follows: (a) secreted vß8 binds to LAP-ß1 with a high affinity with a dissociation constant similar to other TGF-ß receptors (Tucker et al., 1984); (b) both synthetic and endogenous MMP inhibitors block vß8-mediated activation of TGF-ß1; (c) reconstitution of MT1-MMP into the H1264 MT1-MMP–deficient cell line rescues vß8-mediated TGF-ß activation; (d) vß8 and MT1-MMP specifically colocalize in LAP-ß1 substrate contacts; (e) consistent with a proteolytic event, active TGF-ß is liberated by an vß8-dependent mechanism into the supernatants of tumor cell lines and into the aqueous phase of lung cancer xenografts; (f) the proteolytic substrate of vß8-, MT1-MMP–dependent activation of TGF-ß1 is likely to be LAP-ß1, since ß8-overexpressing, MT1-MMP–expressing H1264 cells cleave and inactivate LAP-ß1, whereas ß8-overexpressing, MT1-MMP–deficient H1264 cells do not; (g) cleavage of LAP-ß1 requires the concomitant activity of both ß8 and MT1-MMP, since ß8-specific RGD inhibitors and metalloprotease inhibitors both block cleavage. Precedent for such a proteolytic mechanism is that plasmin (Lyons et al., 1990) and MMP-9 (Yu and Stamenkovic, 2000) have each been shown to activate TGF-ß1 and TGF-ß2, respectively, by cleavage of LAP.
It is also possible that MT1-MMP acts indirectly by proteolytically modifying the activity of vß8 as suggested recently for the MT1-MMP–dependent modification of the integrin vß3 (Deryugina et al., 2000). However, this is unlikely because of the following: (a) cell lines expressing vß8 attach to LAP-ß1 equally well whether or not they express MT1-MMP (unpublished data), suggesting that coexpression of MT1-MMP does not modify the activity of vß8; (b) flow cytometry of H1264 cells overexpressing both ß8 and MT1-MMP using two different anti-ß8 monoclonal antibodies shows no alteration in surface expression of vß8, indicating that antibody epitopes are preserved along with adhesive capability; (c) immunoprecipitations or Western blots of cells coexpressing vß8 and MT1-MMP, using polyclonal antibodies against the cytoplasmic domain of ß8, show no electrophoretic shift or proteolytic degradation products. Therefore, we have no evidence of modification of vß8 by MT1-MMP.
How does MT1-MMP interact with the vß8–TGF-ß1 complex? Our data suggest that upon ligation of vß8 with SLC, vß8 and MT1-MMP become closely associated to form a complex on the cell surface. The cell surface appears to be required for productive interactions, since the secreted forms of vß8 and MT1-MMP do not mediate activation of TGF-ß. Evidence for a physical association on the cell surface is that vß8 and MT1-MMP colocalize in substrate contacts specifically on LAP-ß1. The nature of the MT1-MMP–ß8 interaction awaits elucidation by coimmunoprecipitation and domain interaction studies. Because the localization of MT1-MMP in LAP-ß1 substrate contacts is dependent on the presence of ß8, it is likely that vß8–SLC interactions are required to initiate the recruitment of MT1-MMP. The dynamic recruitment of MT1-MMP to vß8–TGF-ß complexes could provide a basis for the homeostatic regulation of TGF-ß activity in cellular microenvironments.
Although reconstitution of wild-type MT1-MMP is sufficient to support vß8-mediated activation, other metalloproteases could potentially be involved. For instance, MT1-MMP binds to and is potently inhibited by TIMP-2 (Brew et al., 2000), but MT1-MMP–TIMP-2 complexes also serve as a cell surface receptor for MMP-2, and the function of this complex is activation of MMP-2 (Strongin et al., 1995). As such, it is not inconceivable that MMP-2 could also be involved in vß8-mediated activation of TGF-ß. However, in H1264s cells MMP-2 is unlikely to be involved, since TIMP-1, a potent inhibitor of MMP-2 and weak inhibitor of MT1-MMP (Brew et al., 2000), has no effect on vß8-mediated activation of TGF-ß. In contrast, ß8-mediated TGF-ß activation is inhibited by TIMP-2, suggesting that MT1-MMP may alone be sufficient to support ß8-mediated activation of TGF-ß. Although formally we cannot exclude additional roles for other MMPs or related metalloproteases such as ADAMs or ADAMTS, family members in vß8 mediated activation of TGF-ß in other systems or cell types.
The ß8 subunit appears to be the only integrin subunit capable of coordinating metalloprotease activity with SLC bound to the cell surface because the other LAP-ß1 binding integrins are either incapable of activating TGF-ß (Munger et al., 1998) or, in the case of vß6, activating TGF-ß via a metalloprotease-independent pathway (Munger et al., 1999). Furthermore, vß8-mediated TGF-ß activation is solely dependent on metalloproteases and not other proteases because inhibitors of aspartyl, serine, and cysteine proteases do not inhibit activation. Thus, vß8-mediated activation of TGF-ß1 is not dependent on other proteases that have been implicated in SLC activation, including plasmin (Lyons et al., 1990), calpain (Abe et al., 1998), and cathepsin (Lyons et al., 1988).
Integrins (Brooks et al., 1996) and other cell surface molecules (Yu and Stamenkovic, 1999) have also been shown to localize MMP activity to the cell surface. For instance, the integrin vß3 has been shown to form an SDS stable cell surface complex with MMP-2 (Brooks et al., 1996) and to colocalize with MT1-MMP (Deryugina et al., 2001), whereas CD44 has been shown to mediate localization of MMP-9 (Yu and Stamenkovic, 2000) to the cell surface. However, vß3 and CD44 are unlikely to be required for vß8-mediated activation of TGF-ß because vß3 is not expressed in multiple cell lines that support vß8-mediated activation of TGF-ß (Table I) and because anti-CD44 antibodies do not inhibit vß8-mediated activation of TGF-ß (unpublished data).
The selective MMP dependence of vß8- but not vß6-mediated activation of TGF-ß1 clearly demonstrates that the mechanisms of vß8- and vß6-mediated activation of TGF-ß1 are different. A structural basis for these different mechanisms may be the striking difference in the predicted secondary structure of the extracellular domains of the ß8 and ß6 subunits (Moyle et al., 1991). Different integrin-mediated mechanisms of TGF-ß activation may have evolved to support distinct biologic functions. For instance, in the airway epithelium, a site where ß8 is normally expressed (Cambier et al., 2000), a mechanism to support a low and persistent level of activation of TGF-ß1 is necessary for homeostasis (Crawford et al., 1998). We speculate that vß8 could sequester SLC to the cell surface where, in response to an environmental cue, changes in the local balance of MMP/TIMP activity could lead to vß8-dependent liberation of active TGF-ß1. Thus, vß8-mediated activation of TGF-ß1 might liberate the low levels of active TGF-ß1 sufficient to promote local paracrine effects but insufficient for undesirable local and systemic fibrogenic effects of TGF-ß1 (Border and Noble, 1994). Conversely, if vß6 were to liberate TGF-ß by an MMP-dependent mechanism undesirable pathologic levels of TGF-ß might be released locally and into the systemic circulation because after injury expression of vß6 (Breuss et al., 1993; Pilewski et al., 1997) and MMPs (Holgate et al., 1999) are both strongly and rapidly induced.
In summary, abundant evidence implicates the cytokine TGF-ß1, integrins, and MMPs as important mediators of homeostatic cell behaviors. This article provides the first evidence of the coordination of activity of members of these three major multigene families in the maintenance of homeostasis.
|
Materials and methods
|
|---|
Top
Abstract
Introduction
